Viewing Study NCT06243731



Ignite Creation Date: 2024-05-06 @ 8:04 PM
Last Modification Date: 2024-10-26 @ 3:20 PM
Study NCT ID: NCT06243731
Status: NOT_YET_RECRUITING
Last Update Posted: 2024-05-03
First Post: 2024-01-29

Brief Title: A Study of Maribavir in Adults With Kidney Failure Who Have a Cytomegalovirus CMV Infection After Transplantation
Sponsor: Takeda
Organization: Takeda

Study Overview

Official Title: Retrospective Chart Review of Safety Outcomes Associated With Use of Maribavir in Patients With Post-transplant Refractory Cytomegalovirus CMV Infection and Comorbid Endstage Renal Disease ESRD or Comorbid Severe Chronic Renal Disease Requiring Peritoneal Dialysis or Hemodialysis
Status: NOT_YET_RECRUITING
Status Verified Date: 2024-05
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The main aim of this study is to assess the safety profile of maribavir when treating refractory cytomegalovirus CMV infection after transplantation in adults with kidneys that are no longer functioning on their own also called end-stage renal disease or ESRD or have severe chronic kidney disease requiring artificial filtering of the kidney dialysis or the blood hemodialysis

In this study already existing data will be collected from the participants medical records The study will only review data collected as part of the normal clinical routine and will not impact the standard medical care and treatment of participants
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
EUPAS1000000006 REGISTRY EUPAS None